BeaMed is on a journey to reshape laser guided surgery including tumor ablation and epilepsy treatments. BeaMed is developing a unique set of light-based surgical tools and systems that will take today’s minimally invasive treatment options to a whole new level.
At the heart of BeaMed’s technology is the reshaping of the deposited laser energy in real time to perfectly match the tumor or area to be treated, while verifying the shape through advanced imaging modalities.
BeaMed is the inventor and developer of the StingRay Laser System, a novel laser-based thermal ablation technology enabling new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers. The StingRay technology will also allow treatment of previously inoperable cases of epilepsy.
The StingRay System combines new fiber optic technology with an advanced laser console and computerized intelligent control that allows an excellent match between the volume of tumors or the epileptic focal points, and the energy delivered. The accurate matching makes sure we protect vital functional areas against thermal damage. The console integrates advanced imaging modalities, and guides the physician, making sure the treatment is adjusted to the specific patient needs with real time energy control.
The StingRay System is supported by BeaMed’ proprietary technologies that deliver remarkable properties for controlling laser energy. These include:
Directional Laser Interstitial Thermal Therapy or “DiLITT” technology allows full control of the volumetric shape while keeping the energy away from vital areas lowering risk for the patients and improving the clinical outcome.
Extended LITT or “ExLITT” opens new clinical options for treatment of large and irregularly shaped volumes bringing new MIS options to patients who were only eligible for open surgery treatments.
Advanced Planning Module. These are the software tools that control the laser and do the matching between the lesion shape and energy using smart AI based algorithms.
Epilepsy is the most prevalent serious neurologic condition in the world, affecting about 70 million people. Unfortunately, 30%-40% of those patients are afflicted with drug resistant epilepsy, meaning they receive no relief from medication. BeaMed will offer new hope for this core group of patients. In addition, BeaMed’s advanced products will provide better surgical options for Brain tumors.
Lung cancer remains the leading cause of cancer related death today. Major investments and advances have been made in the last decades in robotic and highly precise navigation and diagnostic tools for early stage lung cancer, yet the goal of less invasive therapeutic tools to be deployed through these advanced platforms remains to be solved. BeaMed targets development of new therapeutic options for early stage lung cancer.
Prostate cancer is the most common form of cancer and the second leading cause of death in males. Surgical treatment options carry the risk of erectile dysfunction and urinary incontinence. Better control and shaping of energy deposition to match the target lesion while avoiding critical structures can greatly enhance the tradeoff between outcome and complication rate. BeaMed will aim at altering this tradeoff for millions of patients.
Certification: The company is ISO13485:2016 certified